# Denali (DNLI) — News

DNLI · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/dnli/news

## Recent headlines

- [Denali Therapeutics Inc.: B. Riley raises target price to $35 from $30](https://www.ainvest.com/news/denali-therapeutics-riley-raises-target-price-35-30-2608) — AInvest Wire, Aug 25, 2026
  Denali Therapeutics Inc. (NASDAQ: DNLI) recently announced that B. Riley Securities, Inc. has raised its price target for the company's stock to $35 from $30, while maintaining a "Buy" rating. This adjustment reflects the firm's updated assessment of the company's growth potential and market…
- [Royalty Pharma: Including rights to 1% royalty future net sales](https://www.ainvest.com/news/royalty-pharma-including-rights-1-royalty-future-net-sales-2608) — AInvest Wire, Aug 12, 2026
  Royalty Pharma, a leading entity in the biopharmaceutical royalty sector, has continued to expand its portfolio through strategic transactions that include rights to a percentage of future net sales from various therapeutic products. One such example is the company’s recent agreement with Denali…
- [Denali Therapeutics 2Q loss/share 68c vs. loss/share 72c y/y](https://www.ainvest.com/news/denali-therapeutics-2q-loss-share-68c-loss-share-72c-2608) — AInvest Wire, Aug 6, 2026
- [Denali Therapeutics Q2 total revenue USD 3.6 million](https://www.ainvest.com/news/denali-therapeutics-q2-total-revenue-usd-3-6-million-2608) — AInvest Wire, Aug 6, 2026
  Denali Therapeutics Inc. (Nasdaq: DNLI) reported total revenue of USD 3.6 million for the second quarter of 2026, reflecting continued operations in its pipeline of investigational therapies targeting neurodegenerative and lysosomal storage diseases. The company has not disclosed a breakdown of…
- [Denali Therapeutics received gross proceeds of $195.0M](https://www.ainvest.com/news/denali-therapeutics-received-gross-proceeds-195-0m-2607) — AInvest Wire, Jul 28, 2026
  Denali Therapeutics Inc. recently announced that it has raised $195.0 million in gross proceeds through a financing transaction [1]. The funds will be allocated toward advancing the company’s pipeline of therapeutic candidates, with a focus on late-stage clinical development programs. The financing…

## Similar Stocks

- [BEAM](https://www.lighthorse.io/tickers/beam) — Beam Therapeutics Inc. - Common Stock

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).